Abstract
Introduction: Primary cutaneous lymphomas (PCL) are a heterogeneous group of extra nodal non-Hodgkin lymphomas defined as malignant tumor derived from B, T or natural killer cells. Primary cutaneous follicle centre lymphoma (PCFCL), represents the most common type of primary cutaneous B- Cell Lymphomas. Case Report: We present the case of three female patients with facial PCFCL, all of them with excellent respond to radiotherapy. Discussion: Multiple treatments for PCFCL have been described, including systemic or intralesional Rituximab, surgery or radiotherapy. We present these 3 cases of PCFLC treated with radiotherapy in our service, because of the excellent response, confirming radiotherapy as a therapeutic alternative.
Highlights
Primary cutaneous lymphomas (PCL) are a heterogeneous group of extra nodal non-Hodgkin lymphomas defined as malignant tumor derived from B, T or natural killer cells
According to the latest classification these are divided into 3 groups (WHO EORTC): Primary cutaneous follicle centre lymphoma (PCFCL), primary cutaneous marginal zone lymphoma (PCMZL) and primary cutaneous diffuse large B- cell lymphoma, leg type (PCDLBCL, LT) [3,4]
In the case of our patients the principal side effects where erythema and dry desquamation, well managed with topical treatment. We present these 3 cases of PCFLC treated with radiotherapy in our service, because of the excellent response, supporting radiotherapy as a therapeutic alternative
Summary
The most common type of primary cutaneous B- Cell Lymphomas is the PCFCL, which represents 60% of all cases [5]. Skin lesions presents for several years, with resistance to multiple treatments before diagnostic confirmation is made. Diagnostic confirmation is made by histological study, immunohistochemistry and clonal rearrangement [2]. After the diagnosis is confirmed, staging procedures in addition to history and physical examination should be performed to evaluate for extracutaneous disease and anticipate treatment [6]. This type of cutaneous lymphoma has a good prognosis, with a 5-year survival greater than 95%, but a high risk of recurrence [5]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
